CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024 12:14 ET
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024 11:23 ET
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024 10:00 ET
|
CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
September 27, 2023 10:12 ET
|
The Insight Partners
Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...
Theralase® Releases FY2022 Audited Financial Statements
April 26, 2023 18:01 ET
|
Theralase Technologies Inc.
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Phase Ib NMIBC Clinical Study Published
June 21, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
CAST Founder to Speak at BCG-led Virtual Software Intelligence Forum 2022
January 10, 2022 10:07 ET
|
CAST Software Inc.
NEW YORK and PARIS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CAST Founder & CEO, Vincent Delaroche, will be joining Benjamin Rehberg, BCG Senior Partner & Head of Technology Practice NA, as he...
Theralase Releases 3Q21 Financial Statements and Newsletter
November 29, 2021 18:00 ET
|
Theralase Technologies Inc.
TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...